Bristol-Myers Squibb executives did their best to talk up the six near-term product launches they’re expecting from its $74 billion merger with Celgene during the company’s fourth-quarter earnings release.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,